Cartherics to present at the 2023 BIO International Convention

Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it is presenting at the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts. CEO Prof. Alan Trounson will meet with senior biotech executives, business development leaders and investors to discuss the company’s technology and development program.

The BIO International Convention is the Biotechnology Innovation Organization (BIO) premier annual event and is the world’s largest industry gathering, which brings together thousands of global biotechnology and pharmaceutical leaders. The four-day, in-person event includes networking, programming and partnering opportunities.

Prof. Trounson will be presenting at 3:45pm on Wednesday 7th June (EDT). His presentation will detail Cartherics’ pipeline, R&D activities, business objectives, and investment goals – with a view to engaging with potential investors and partners.

Cartherics’ portfolio includes an autologous CAR-T cell product scheduled to enter the clinic in 2024 for the treatment of ovarian cancer and an allogeneic immune cell platform consisting of CAR-iNK and CAR-iT cell products targeting solid tumours (ovarian, gastric and other cancers) derived from gene edited induced pluripotent stem cells (iPSCs).  The lead CAR-iNK product is expected to enter clinical trials in 2025.

“BIO is a special place to present for a biotech company because most of the industry is represented there, with great partnering opportunities and potential investment interests.  It allows us to present our exciting immune therapies developments to the world,” said Prof. Trounson.

Download presentation


About Cartherics

Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered to provide enhanced function for the derived NK and other immune cells.

The Company is also developing autologous CAR-T cell therapies. These use the patient’s own immune system T cells, which are modified to be effective against the patient’s cancer cells.  CTH-004 is created by genetically modifying patient T cells to insert a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes that are involved in suppression of T cell function.

Media Contact

Christine Filippis

Phone: +61 419 119 866